Vaxart Stock Is Trading Higher As FDA Clears Mid-Stage Trial For S-Only Oral COVID-19 Vaccine Candidate

  • The FDA has signed off Vaxart Inc's VXRT Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate.
  • "This is great news because it allows us to move forward with our first S-only vaccine construct," said Andrei Floroiu, Vaxart's Chief Executive Officer. "As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial."
  • "This new clinical trial will allow us to compare the S-only and S+N vaccine candidates and put us in a position to decide which approach offers the best way forward for our COVID-19 vaccine development program, particularly in the face of emerging variant strains."
  • The Phase 2 clinical trial with the S-only construct is expected to start in 2H of 2021.
  • Related: Vaxart's Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants.
  • Price Action: VXRT shares are up 12% at $8.05 during the premarket session on the last check Monday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefsCOVID-19 VaccinePhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!